GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Xilong Scientific Co Ltd (SZSE:002584) » Definitions » Operating Income

Xilong Scientific Co (SZSE:002584) Operating Income : ¥132 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Xilong Scientific Co Operating Income?

Xilong Scientific Co's Operating Income for the three months ended in Mar. 2024 was ¥33 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥132 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Xilong Scientific Co's Operating Income for the three months ended in Mar. 2024 was ¥33 Mil. Xilong Scientific Co's Revenue for the three months ended in Mar. 2024 was ¥2,180 Mil. Therefore, Xilong Scientific Co's Operating Margin % for the quarter that ended in Mar. 2024 was 1.50%.

Warning Sign:

Xilong Scientific Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -15.2%.

Xilong Scientific Co's 5-Year average Growth Rate for Operating Margin % was -15.20% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Xilong Scientific Co's annualized ROC % for the quarter that ended in Mar. 2024 was 3.33%. Xilong Scientific Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.04%.


Xilong Scientific Co Operating Income Historical Data

The historical data trend for Xilong Scientific Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilong Scientific Co Operating Income Chart

Xilong Scientific Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 135.53 125.97 180.74 128.12 144.69

Xilong Scientific Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.93 27.26 32.80 39.70 32.62

Xilong Scientific Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥132 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xilong Scientific Co  (SZSE:002584) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Xilong Scientific Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=130.468 * ( 1 - 18.59% )/( (3174.827 + 3198.713)/ 2 )
=106.2139988/3186.77
=3.33 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4769.004 - 1034.287 - ( 559.89 - max(0, 2069.737 - 3329.294+559.89))
=3174.827

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4676.907 - 1004.145 - ( 474.049 - max(0, 2033.891 - 3240.754+474.049))
=3198.713

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Xilong Scientific Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=84.344/( ( (845.7 + max(1262.887, 0)) + (861.433 + max(1202.925, 0)) )/ 2 )
=84.344/( ( 2108.587 + 2064.358 )/ 2 )
=84.344/2086.4725
=4.04 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1392.66 + 561.663 + 486.872) - (1034.287 + 0 + 144.021)
=1262.887

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1303.034 + 568.302 + 487.818) - (1004.145 + 0 + 152.084)
=1202.925

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Xilong Scientific Co's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=32.617/2180.465
=1.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Xilong Scientific Co Operating Income Related Terms

Thank you for viewing the detailed overview of Xilong Scientific Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Xilong Scientific Co (SZSE:002584) Business Description

Traded in Other Exchanges
N/A
Address
F21 DS Building, 538 North Dezheng Road, Guangzhou, CHN, 510045
Xilong Scientific Co Ltd operates as a chemical reagents manufacturers and suppliers in China. Its products include chemical reagents (sulfuric acid, calcium hydroxide, ethanol, acetylacetone, nitric acid, ammonia solution, benzyl alcohol, ethanol, etc.), lab glassware (bottles, dish and tube; burning glass, measuring vessel and other lab glassware) and chemical raw materials (caustic soda flake, hydrochloric acid, sodium hydroxide).
Executives
Huang Wei Peng Director
Huang Wei Bo Director
Huang Zhen Kai Directors, executives
Huang Shao Qun Directors, executives
Liu Feng Supervisors
Wei Ying Yin Executives
Chen Biao Directors, executives
Li Shu Yan Supervisors
Mou Yong Supervisors
Wang Qi Guang Executives

Xilong Scientific Co (SZSE:002584) Headlines

No Headlines